Vaginal Yeast Infections treatment, Oral Ibrexafungerp, receives FDA Acceptance and Priority Review of New Drug Application

SCYNEXIS, Inc., a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the SCYNEXIS's New Drug Application (NDA) for ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC), also known as vaginal yeast infections. The FDA has granted [...]

The post Vaginal Yeast Infections treatment, Oral Ibrexafungerp, receives FDA Acceptance and Priority Review of New Drug Application appeared first on Outbreak News Today.